TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06343805: A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-M

Sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 256 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$1,665,660

Rescue Site Savings

+$1,102,620

Unlock Full NCT06343805 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06343805 Rescue Dossier →